AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04485182 — intervention group
Intervention type: OTHER
Intervention: Underwater jet massage (Tangentor)
Description: Underwater jet massage (Tangentor) would be performed in a tub developed for this purpose, where the water temperature: 33-35 ° C. The treatments lasting from 15 atm and 15 cm for 15 minutes.~They take a minimum of 10 treatments for approx. under 2 weeks.
Study NCT03203395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening and counselling
Description: Screening for symptoms of depression and anxiety in heart patients, giving advice for prevention and managing of such symptoms and stimulating collaborative care between the hospital and the general practitioner.
Study NCT03742921 — intervention group
Intervention type: DRUG
Intervention: Istodax
Description: Istodax
Study NCT03501641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: image-based virtual reality learning
Description: The participants will use a whole-view, 360 degree image-based virtual reality to learn a competence of history taking and physical examination for otolaryngology and they can see the response of the staffs and standard patients (including image, voice, face expression, movement, ... etc).
Study NCT03501641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: video-based learning
Description: voice of the staffs and standard patients.
Study NCT04202601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Arms 1: Neoadjuvant therapy group 20 patients Drug: Sintilimab Weight\<60Kg: 3mg/kg Q3W Weight>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Perioperative Sintilimab+IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .~Arms 2: first-line therapy group, 30 patients Drug: Sintilimab Weight\<60Kg: 3mg/kg Q3W Weight>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.~Arms 3: ≥second-line therapy group, 30 patients Drug: Sintilimab Weight\<60Kg: 3mg/kg Q3W Weight>=60Kg:200 mg Q3W on Day 1 by IV infusion; Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.
Study NCT04202601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: Arms 1: Neoadjuvant therapy group, 20 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Perioperative Sintilimab+ IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .~Arms 2: first-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.~Arms 3: ≥second-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.
Study NCT00904449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER
Description: 10mg, 20mg, and 40mg PO
Study NCT04402138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib 100 mg BID will be self-administered orally starting from 100 day (+/- 7 days) Post-BMT on a 28-day schedule, with or without food, until the patient has reached approximately 2 years post-BMT.
Study NCT04701827 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AWARE intervention
Description: Comprehensive 360 degrees intervention. The intervention targets multiple aspects of the described enhancers of functioning based on on the ICF Brief Core Set. 1) ADL ability as a part of carrying out daily routines 2) Mood symptoms, medication and side effects 3) Social, relatives and network 4) Physical health, including BMI, biomarkers and exercise5) Cognition, circadian rhythm measured as sleep quality, and coping (stress reduction).
Study NCT05684822 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Acupoint:Taichong, Shenmen, Neiguan points with twice a week for total three weeks
Study NCT05684822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupoint:Taichong, Shenmen, Neiguan points with twice a week for total three weeks
Study NCT02302599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells
Description: Infusion treatment
Study NCT02302599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Controlled suspension liquid
Description: Infusion treatment
Study NCT02123901 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking Meditation
Description: Walking Meditation training program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking on the treadmill while concentrated on foot stepping by voiced Budd and Dha with each foot step that contacted the floor to practice mindfulness while walking. Walking Meditation will be conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week.
Study NCT02123901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Meditation
Description: Walking Meditation training program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking on the treadmill while concentrated on foot stepping by voiced Budd and Dha with each foot step that contacted the floor to practice mindfulness while walking. Walking Meditation will be conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week.
Study NCT02123901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Description: Walking training program will be based on aerobic walking exercise. The subjects will perform walking on the treadmill and conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week.
Study NCT02123901 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No exercise
Description: Sedentary life style.
Study NCT02552043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nintendo Wii exercise program
Description: The aerobic training protocol was designed to improve muscular strength, body endurance and flexibility (involved activities as: running, up the knees, butt kickers, etc.). The game used has a strap pouch to hold the Nunchuk© controller placed on the thigh that detects the lower body movements, and also features a number of exercise options supervised by a virtual personal trainer
Study NCT02792686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: Single Administration
Study NCT03377608 — intervention group
Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate
Description: Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit
Study NCT03377608 — intervention group
Intervention type: DRUG
Intervention: Depo-Provera
Description: Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit
Study NCT01294553 — intervention group
Intervention type: DRUG
Intervention: Administration of rosiglitazone/metformin
Description: Subjects who are administered rosiglitazone/metformin at least once
Study NCT03077334 — intervention group
Intervention type: DEVICE
Intervention: PET-CT
Description: PET-CT will be done before operation and that is routine treatment procedure for pancreatic cancer.
Study NCT01217229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Capsules administered once or twice daily, continuous dosing. Subjects will begin with 900 mg/day, but should safety data allow in our PLX108-01 study, subject may dose at 1200 mg/day.
Study NCT01481844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole , Tab Amoxycillin , Tab Clarithromycin ,Tab Tinidazole
Description: use of Sequential therapy as second line treatment for eradication H pylori currently Sequential therapy is indicated as first line treatment for H pylori eradication
Study NCT01481844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline
Description: this combination is standard of care as H pylori second line treatment
Study NCT02665390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous cryoablation
Description: Percutaneous cryoablation
Study NCT01151189 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A/AERAS-485
Description: Subjects received intradermal injection of MVA85A/AERAS-485 on Study Day 0, followed 6-9 months later by a booster injection of MVA85A/AERAS-485.
Study NCT01151189 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received an intradermal injection placebo on Study Day 0, followed 6-9 months later by a booster injection of placebo.
Study NCT03729739 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: QFR-based diagnostic strategy
Description: Novel computer based calculation of lesion severity. Pressure wire-free and adenosine-free
Study NCT03729739 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FFR-based diagnostic strategy
Description: Standard FFR based diagnostic method. Pressure drop across the stenosis is measured with a pressure wire during medical induced hyperaemic conditions
Study NCT02080806 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Insufflation Exsufflation
Description: Mechanical Insufflation Exsufflation -Each patient received daily treatments by means of a light-weight, elastic oronasal mask. Treatments were divided between morning and afternoon and were carried out 5 times a week. A total of 20 sessions were carried out by a a trained respiratory therapist.
Study NCT04529902 — intervention group
Intervention type: DRUG
Intervention: Tumor Necrosis Factor Inhibitors
Description: TNFi claim is used as the reference group.
Study NCT04529902 — intervention group
Intervention type: DRUG
Intervention: Abatacept
Description: Abatacept claim is used as the exposure group.
Study NCT00966277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: 5000 units subcutaneous, by injection under the skin, daily for 16 weeks
Study NCT05748691 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical implementation of hs-cTnT
Description: To investigate the clinical impact on the transition from a hs-cTnI assay to a hs-cTnT assay in consecutive patients presenting to the Emergency Department or Acute Medical Unit with suspected acute coronary syndrome.
Study NCT04503343 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: non-drug intervention
Description: mindfulness training, relaxation training, or electrical cerebellar stimulation
Study NCT01975974 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Description: Using ultrasound as a guide for peripheral venous cannulation in obese patients
Study NCT02875977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: A 4-minute educational video describing PFPT
Study NCT02875977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational handout
Description: A 2-page educational handout describing PFPT
Study NCT02875977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational handout
Description: A 2-page educational handout describing PFPT
Study NCT02754817 — intervention group
Intervention type: DRUG
Intervention: insulin degludec/liraglutide
Description: This is a non-interventional, chart review study and the patients are treated according to current clinical practice and local licenses upon the treating physicians' decision.
Study NCT00841880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril + Felodipine
Description: Ramipril 5mg + Felodipine 5mg once a day
Study NCT00841880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: 10 mg once a day
Study NCT00841880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: 5mg once a day
Study NCT00841880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: 5mg once a day
Study NCT04606043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sandblasting
Description: Sandblasting will be applied onto the vestibular surfaces of the teeth before applying the etchant.
Study NCT04606043 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acid Etching
Description: Only acid etching will be applied onto the vestibular surfaces of the teeth before rebonding
Study NCT06084156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653
Description: Part 1: Day 1 to Day 4, not take; Part 2: Day 6 - Take HSK7653 35 mg; HSK7653 25 mg on day 13, day 20, day 27, and day 34; Part 3: Day 41 - Take HSK7653 25 mg
Study NCT06084156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Part 1: Day 1 to Day 4, 1000mg BID; Part 2: Not take; Part 3: Day 38- day 47, 1000mg BID
Study NCT01442818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilaudid PCA
Description: PCA setting of 0.3mg demand dose, 8 minute lock out interval, and 5mg 4-hour limit.
Study NCT01442818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilaudid IV Scheduled
Description: Nurse administered IV Dilaudid 0.5mg every 2 hours.
Study NCT04646915 — intervention group
Intervention type: OTHER
Intervention: Day surgery
Description: Patients with CuRC who meet the standards will be assigned to day surgery center for surgery
Study NCT01517646 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: The Zeltiq System
Description: Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
Study NCT01718353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOCETAXEL (XRP6976)
Description: Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
Study NCT01718353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CABAZITAXEL (XRP6258)
Description: Pharmaceutical form: Concentrate and solvent for solution for infusion Route of administration: Intravenous
Study NCT01718353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study NCT04299438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol Hydrochloride
Description: 2mg/mL vials
Study NCT04299438 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% saline in vials matching the vials of the active drug
Study NCT02881905 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ball attachment
Description: it is attachment part that connects the overdenture to the implant
Study NCT02881905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cm loc attachment
Description: It is a new attachment made of peek material
Study NCT02262091 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food fibers
Study NCT02262091 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study NCT02262091 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (incl. criterion)
Study NCT02262091 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Influenza vaccine (incl. criterion)
Study NCT01651442 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Insomnia Therapy
Description: Sleep hygiene, stimulus control, and sleep restriction presented in four sessions.
Study NCT01651442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: 5mg or 10mg
Study NCT01651442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: 50mg to 150mg
Study NCT01651442 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy
Description: Cognitive restructuring, constructive worry, behavioral experiments presented in four sessions.
Study NCT02364843 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid: Threonine
Description: Each of the 18 infants will have a different intake of dietary amino acid threonine for a 24 period and by cross-over regression analysis a break-point or requirement will be established
Study NCT01696838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Patients receive electroacupuncture for 30 minutes with a stimulation frequency of 2 /100 Hz and a stimulation intensity varying from 0.1 to 1.0 mA.3 times per week,the duration is 12 weeks.
Study NCT01696838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moxibustion
Description: patients receive herbs-partitioned moxibustion for 2 cones，3 times a week for 12 weeks.
Study NCT03566654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic conditioning
Description: RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times， two times per day. The duration of the treatment is 30+/-2days.
Study NCT03566654 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ambulatory blood pressure monitoring
Description: A diagnostic technique for measuring blood pressure in daily life by means of automatic intermittent timing. Because ABPM has overcome the limitations of clinic blood pressure measurement, observation error and white coat effect, it can objectively reflect the actual level and fluctuation of blood pressure. Each patient of the two arms will use ABPM measure blood pressure before and after RIC or sham RIC treatment.
Study NCT03566654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ambulatory blood pressure monitoring
Description: A diagnostic technique for measuring blood pressure in daily life by means of automatic intermittent timing. Because ABPM has overcome the limitations of clinic blood pressure measurement, observation error and white coat effect, it can objectively reflect the actual level and fluctuation of blood pressure. Each patient of the two arms will use ABPM measure blood pressure before and after RIC or sham RIC treatment.
Study NCT03566654 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Sham RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times. The duration of the treatment is 30+/-2days.
Study NCT01545323 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: One 20cm2/10cm2 autologous skin sheet graft
Description: Adults will receive a graft of approximately 20cm2. Children under 16 years of age will receive a graft around half this size, around 10cm2 .The graft is derived from SPINK5 transduced cells
Study NCT03390647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6130
Description: Oral dose
Study NCT03390647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E6130-matched placebo
Study NCT00371228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delay of umbilical cord clamping
Description: Umbilical cord delayed until pulsation stops.
Study NCT00851448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral nutritional supplement, food for special medical purposes
Description: 2 servings of 200-300 ml per day, treatment period: 16 weeks
Study NCT00851448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: oral nutritional supplement, food for special medical purposes
Description: 2 servings of 200-300 ml per day, treatment period: 16 weeks
Study NCT02729831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive decision aid
Description: The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis
Study NCT02729831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video decision aid
Description: Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
Study NCT02729831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Report
Description: A short report that includes the patients' goals and treatment preferences
Study NCT00250939 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myozyme
Description: 20 mg/kg qow
Study NCT03751566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Schedule of the acupuncture:~Acupuncture may be done ambulant or during hospitalisation . Acupuncture will be administered 1-3 times a week ( in case of severe toxicity and problems caused by the radiotherapy, it may continue also after the termination of the radiotherapy.) Acupuncture needles will be left for 5- 30 minutes, as per individual need of the patients.~Acupuncture will be performed by a physician trained in acupuncture.
Study NCT03751566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard supportive therapy
Description: Standard supportive therapy